1512. HIV-1 subtypes and antiretroviral resistance mutations in HBV/HCV co-infected HIV-1 positive patients in Turkey
Session: Poster Abstract Session: HIV and Co-infections
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
  • HIV poster idsa silaakhan.pdf (231.4 kB)
  • Background: Co-infection with either HBV or HCV in HIV-1 positive patients is not very common, but possible since all these viruses share transmission routes and geographical distribution. Interaction between these viruses generally amplifies liver damage, increasing the risk of developing end-stage liver disease and hepatocellular carcinoma. HIV-HCV co-infection is associated with poorer response to antiviral therapy.  The objectives of this study were to determine the subtypes and the primary ART resistance mutations in HBV/HCV co-infected HIV-1 positive Turkish patients. 

    Methods: We have 29 co-infections as follows: 25 HIV + HBV and 4 HIV + HCV. HIV-1 subtypes and CRFs were identified by phylogenetic analysis (neighbore – joining method) via sequencing of HIV-1 polgene. HIV-1 ART resistance mutations were analyzed according to criteria by the WHO 2009 list of surveillance drug resistance mutations. The demographic, clinical and laboratory features of the HIV-1 positive patients co-infected with HBV/HCV has been shown in the Table 1. 

    Results: The molecular evidence in this study indicates subtype B (15/29, 52%) and CRFs (11/29, 38%) of HIV-1 are most prevalent subtypes, respectively. Primary ART resistance mutation (NRTI; T215D, M41L + T215D, K70E + M184V) were detected in 3/29 (10%) naïve Turkish patients and secondary ART resistance mutations (NRTI; M41L + T215C, NNRTI; K103N) were detected in 2/29 (6.9%) Turkish patients on the ART treatment.                  

    Conclusion: This study revealed the subtype/CRF of HIV-1 in HBV/HCV co-infections from different center in Turkey. HIV-1 molecular epidemiology studies are important tools for tracking transmission patterns and the spread of CRF and monitoring of CRF subtypes of HIV-1 in globally scale may be important in vaccine development against HIV. However, the high prevalence of HIV-1 primary resistance mutations in such as patients suggested that the resistance testing must be an integral part of the management of HIV-1 infection and the choice of first - line therapy regime should be guided by the results of genotypic resistance in Turkey.

    Murat Sayan, associate prof.dr.1, Sila Akhan, Prof.Dr.2, Fatma Sargin, MD3, Atahan Cagatay4, Hayati Demiraslan5, Elif Altunok6 and Aynur Aynioglu6, (1)PCR Unit, Kocaeli University Medical Faculty, Kocaeli, Turkey, (2)Infectious Diseases and Clinical Microbiology, Kocaeli University Medical Faculty, Kocaeli, Turkey, (3)Istanbul Medeniyet University, istanbul, Turkey, (4)Infectious Diseases, Istanbul Medical Faculty, Istanbul, Turkey, (5)Erciyes University Medical Faculty, kayseri, Turkey, (6)Kocaeli University Medical Faculty, Kocaeli, Turkey


    M. Sayan, None

    S. Akhan, None

    F. Sargin, None

    A. Cagatay, None

    H. Demiraslan, None

    E. Altunok, None

    A. Aynioglu, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.